Approval · Notice of Compliance 28007 · 2022
DAPTOMYCIN FOR INJECTION: Notice of Compliance 28007
Issued April 22, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28007
- Date
- April 22, 2022
- Company
- Dr Reddys Laboratories Ltd
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- New format
- Canadian reference product
- CUBICIN (Cubist Pharmaceuticals Llc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DAPTOMYCIN FOR INJECTION | 02526743 | Cancelled Pre Market |
Medicinal ingredients
- DAPTOMYCIN 350 MG per VIAL